Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Quality of Life Research
Erschienen in: Quality of Life Research 11/2016

03.06.2016

Health-related quality of life in patients with psoriasis: a systematic review of the European literature

verfasst von: Montse Obradors, Carles Blanch, Marta Comellas, Montse Figueras, Luis Lizan

Erschienen in: Quality of Life Research | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To summarize the data published over the last 5 years in the European Union related to the health-related quality of life (HRQoL) of patients with psoriasis and its conditioning factors.

Methods

International electronic databases and gray literature were searched to identify studies conducted on patient-reported outcomes in patients with psoriasis, published in Europe between January 1, 2009 and December 31, 2013. Bibliographic references were hand-searched. Editorials, letters, commentaries, opinion papers, and studies related to specific treatments were excluded.

Results

A total of 46 studies met the inclusion criteria, 27 of them reporting data related to HRQoL or its conditioning factors. The publications reviewed highlighted the substantial negative impact of psoriasis on patients’ HRQoL. Most of the studies that analyzed the relationship between HRQoL and sociodemographic characteristics described a relation between gender (female) and age (young patients) and poorer HRQoL. An association between HRQoL impairment and visibility of skin lesions and disease activity and severity was also established. Skin discomfort and pruritus were identified as elements that negatively influenced HRQoL. Use of biological agents had a positive impact on HRQoL and on treatment satisfaction, a better HRQoL being seen in patients treated with systemic therapies and biologics.

Conclusions

HRQoL has been broadly addressed in patients with psoriasis in Europe. Several disease- and patient-related factors contributed to its deterioration. Therapeutic measures with proven effectiveness in controlling disease symptoms and reducing PASI should be considered in patients with a severe disease who have a poorer HRQoL.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Langley, R. G. B., Krueger, G. G., & Griffiths, C. E. M. (2005). Psoriasis: Epidemiology, clinical features, and quality of life. Annals of the Rheumatic Diseases, 64(suppl 2), ii18–ii23.PubMedPubMedCentral
2.
Perera, G. K., Di Meglio, P., Frank, O., & Nestle, F. O. (2012). Psoriasis. Annual Review of Pathology: Mechanisms of Disease, 7, 385–422.CrossRef
3.
Ortonne, J. P., & Prinz, J. C. (2004). Alefacept: A novel and selective biologic agent for the treatment of chronic plaque psoriasis. The European Journal of Dermatology, 14, 41–45.PubMed
4.
Lebwohl, M. G., Bachelez, H., Barker, J., Girolomoni, G., Kavanaugh, A., Langley, R. G., et al. (2014). Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. Journal of the American Academy of Dermatology, 70(5), 871–881.CrossRefPubMed
5.
Tan, X., Feldman, S. R., & Balkrishnan, R. (2012). Quality of life issues and measurement in patients with psoriasis. Psoriasis: Targets and Therapy, 2(1), 13–23.
6.
Rapp, S. R., Feldman, S. R., Exum, M. L., Fleischer, A. B, Jr., & Reboussin, D. M. (1999). Psoriasis causes as much disability as other major medical disease. Journal of the American Academy of Dermatology, 41(3 Ot 1), 401–407.CrossRefPubMed
7.
Fowler, J. F., Duh, M. S., Rovba, L., Buteau, S., Pinheiro, L., Lobo, F., et al. (2008). The impact of psoriasis on health care costs and patient work loss. Journal of the American Academy of Dermatology, 59(5), 772–780.CrossRefPubMed
8.
Bhosle, M. J., Kulkarni, A., Feldman, S. R., & Balkrishnan, R. (2006). Quality of life in patients with psoriasis. Health and Quality of Life Outcomes, 4(1), 35–37.CrossRefPubMedPubMedCentral
9.
Both, H., Essink-Bot, M. L., Busschbach, J., & Nijsten, T. (2007). Critical review of generic and dermatology-specific health-related quality of life instruments. Journal of Investigative Dermatology, 127(12), 2726–2739.CrossRefPubMed
10.
Higgins, J. P. (Ed.). (2008). Cochrane handbook for systematic reviews of interventions (Vol. 5). Chichester: Wiley.
11.
12.
13.
Norlin, J. M., Steen Carlsson, K., Persson, U., & Schmitt-Egenolf, M. (2012). Analysis of three outcome measures in moderate to severe psoriasis: A registry-based study of 2450 patients. British Journal of Dermatology, 166(4), 797–802.CrossRefPubMed
14.
Daudén, E., Conejo, J., & García-Calvo, C. (2011). Percepción del médico y paciente de la gravedad de la psoriasis, su impacto en la calidad de vida y satisfacción con la atención y el tratamiento recibido. Estudio observacional en España. Actas Dermo-Sifiliográficas, 102(4), 270–276.CrossRef
15.
Anstey, A., McAteer, H., Kamath, N., & Percival, F. (2012). Extending psychosocial assessment of patients with psoriasis in the UK, using a self-rated, web-based survey. Clinical and Experimental Dermatology, 37, 735–740.CrossRefPubMed
16.
Sampogna, F., Tabolli, S., & Abeni, D. (2012). Living with psoriasis: Prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Dermato-Venereologica, 92, 299–303.CrossRefPubMed
17.
Tadros, A., Vergou, T., Stratigos, A., Tzavara, C., Hletsos, M., Katsambas, A., et al. (2011). Psoriasis: Is it the tip of the iceberg for the quality of life of patients and their families? Journal of the European Academy of Dermatology and Venereology, 25, 1282–1287.CrossRefPubMed
18.
Böhm, D., Stock Gissendanner, S., Bangemann, K., Snitjer, I., Werfel, T., Weyergraf, A., et al. (2013). Perceived relationships between severity of psoriasis symptoms, gender, stigmatization and quality of life. Journal of the European Academy of Dermatology and Venereology, 27, 220–226.CrossRefPubMed
19.
Daudén, E., Herrera, E., Puig, L., Sánchez-Carazo, J. L., Toribio, J., & Perulero, N. (2013). Impact of active and stable psoriasis on health-related quality of life: The PSO-LIFE study. Actas Dermo-Sifiliográficas, 104(8), 685–693.CrossRefPubMed
20.
Lindberg, M., Isacson, D., & Bingefors, K. (2013). Self-reported skin diseases, quality of life and medication use: A nationwide pharmaco-epidemiological survey in Sweden. Acta Dermato-Venereologica, 94(2), 188–191.CrossRef
21.
Blome, C., Simianer, S., Purwins, S., Laass, A., Rustenbach, S. J., Schaefer, I., et al. (2010). Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology, 221, 154–159.CrossRefPubMed
22.
Daudén, E., Pujol, R. M., Sánchez-Carazo, J. L., Toribio, J., Vanaclocha, F., Puig, L., et al. (2013). Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study. Actas Dermo-Sifiliográficas, 104, 807–814.PubMed
23.
Miniszewska, J., Chodkiewicz, J., Ograczyk, A., & Zalewska-Janowska, A. (2013). Optimism as a predictor of health-related quality of life in psoriatics. Postępy Dermatologii i Alergologii, 30(2), 91–95.PubMedPubMedCentral
24.
Miniszewska, J., Juczyski, Z., Ograczyk, A., & Zalewska, A. (2013). Health-related quality of life in psoriasis: Important role of personal resources. Acta Dermato-Venereologica, 93(5), 551–556.CrossRefPubMed
25.
Fernandez-Torres, R. M., Paradela, S., & Fonseca, E. (2012). Psoriasis in patients older than 65 years. A comparative study with younger adult psoriatic patients. The Journal of Nutrition, Health & Aging, 16, 586–589.CrossRef
26.
Hernánz, J. M., Sánchez-Regaña, M., Izu, R., Mendiola, V., & García-Calvo, C. (2012). Clinical and therapeutic evaluation of patients with moderate to severe psoriasis in Spain: The Secuence Study. Actas Dermo-Sifiliográficas, 103(10), 897–904.CrossRef
27.
Cozzani, E., Borrini, V., Pennella, A., Burlando, M., Cardo, P., Rebora, A., et al. (2010). The quality of life in Italian psoriatic patients treated with biological drugs. Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa italiana di dermatologia e sifilografia, 145(6), 709–712.
28.
Pereira, M. G., Brito, L., & Smith, T. (2012). Dyadic adjustment, family coping, body image, quality of life and psychological morbidity in patients with psoriasis and their partners. The International Journal of Behavioral Medicine, 9(3), 260–269.CrossRef
29.
Richards, H. L., Fortune, D. G., Griffiths, C. E., & Main, C. J. (2001). The contribution of perceptions of stigmatization to disability in patients with psoriasis. The Journal of Psychosomatic Research, 50, 11–15.CrossRefPubMed
30.
Gupta, M. A., Gupta, A. K., & Watteel, G. N. (1998). Perceived deprivation of social touch in psoriasis is associated with greater psychologic morbidity: An index of the stigma experience in dermatologic disorder. Cutis, 61, 339–342.PubMed
31.
Palotai, T., Szepietowski, J. C., Pec, J., Arenberger, P., Giurcaneanu, C., Gyulai, R., et al. (2010). A survey of disease severity, quality of life, and treatment patterns of biologically naïve patients with psoriasis in Central and Eastern Europe. Acta Dermatovenerologica Croatica, 18(3), 151–162.
32.
Panigalli, S., Coccarielli, D., Germi, L., Trevisan, G. P., & Veller-Fornasa, C. (2009). Non-randomized pilot study on the evaluation of the quality of life and psychosocial stress before and after systemic therapy in patients affected by moderate to severe psoriasis. Journal of Biological Regulators and Homeostatic Agents, 23(2), 111–117.PubMed
33.
Ghatnekar, O., Ljungberg, A., Wirestrand, L. E., & Svensson, A. (2012). Cost and quality of life for psoriatic patients at different degrees of severity in southern Sweden—A cross-sectional study. The European Journal of Dermatology, 22(2), 238–2345.PubMed
34.
Jacobi, A., Kupke, C., Behzad, M., & Hertl, M. (2013). Comorbidities, metabolic risk profile and health-related quality of life in German patients with plaque-type psoriasis: A cross-sectional prospective study. International Journal of Dermatology, 52, 1081–1087.CrossRefPubMed
35.
Ljosaa, T. M., Mork, C., Stubhaug, A., Moum, T., & Wahl, A. K. (2012). Skin pain and skin discomfort is associated with quality of life in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 26, 29–35.CrossRefPubMed
36.
Reich, A., Hrehorow, E., & Szepietowski, J. C. (2010). Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Dermato-Venereologica, 90(3), 257–263.CrossRefPubMed
37.
Finlay, A. Y., & Khan, G. K. (1994). Dermatology Life Quality Index (DLQI)—A simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19(3), 210–216.CrossRefPubMed
38.
Ghajarzadeh, M., Ghiasi, M., & Kheirkhah, S. (2012). Associations between skin disease and quality of life: A comparision of psoriasis, vitiligo, and alopecia areata. Acta Medica Iranica, 50(7), 511–515.PubMed
39.
Pärna, E., Aluoja, A., & Kingo, K. (2015). Quality of life and emotional state in chornic skin disease. Acta Dermato-Venereologica, 95(3), 312–316.CrossRefPubMed
40.
Martínez-García, E., Arias-Santiago, S., Valenzuela-Salas, I., Garrido-Colmenero, C., García-Mellado, V., & Buendía-Eisman, A. (2014). Quality of life in persons living with psoriasis patients. Journal of the American Academy of Dermatology, 71, 302–307.CrossRefPubMed
41.
Takeshita, J., Duffin, K. C., Shin, D. B., Krueger, G. G., Robertson, A. D., Troxel, A. B., et al. (2014). Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. Journal of the American Academy of Dermatology, 71(4), 633–641.CrossRefPubMedPubMedCentral
42.
Viswanathan, H. N., Chau, D., Milmont, C. E., Yang, W., Erondu, N., Revicki, D. A., et al. (2014). Total Skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. Journal of Dermatological Treatment, 31, 1–5.
43.
Mattei, P. L., Corey, K. C., & Kimball, A. B. (2014). Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): The correlation between disease severity and psychological burden in patients treated with biological therapies. Journal of the European Academy of Dermatology and Venereology, 28, 333–337.CrossRefPubMed
44.
Moreno-Ramírez, D., Fonseca, E., Herranz, P., & Ara, M. (2010). Realidad terapéutica de la psoriasis moderada-grave en España. Encuesta de opinión. Actas Dermo-Sifiliográficas, 101(10), 858–865.CrossRef
45.
Hägg, D., Sundström, A., Eriksson, M., & Schimitt-Egenolf, M. (2015). Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI). Journal of the European Academy of Dermatology and Venereology, 9(3), 452–456.CrossRef
46.
Mrowietz, U., Kragballe, K., Reich, K., Spuls, P., Griffiths, C. E., Nast, A., et al. (2011). Definition of treatment goals for moderate to severe psoriasis: A European consensus. Archives of Dermatological Research, 303, 1–10.CrossRefPubMed
47.
Melero, R., Ibánez, D., Tiemblo, C., Díez, B., del Arco, J., García, M. Á., & Castro, M. B. (2011). [Estudio Psoriafarm Bizkaia: características más relevantes]. Pharmaceutical Care España, 13(2), 74–90.
48.
Norlin, J. M., Carlsson K. S., Persson, U., & Schmitt-Egenolf, M. (2012b). Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-word practice. Dermatology, 225(4), 326–332.CrossRefPubMed
49.
Palijan, T. Z., Kovacevic, D., Koic, E., Ruzic, K., & Dervinja, F. (2011). The impact of psoriasis on the quality of life and psychological characteristics of persons suffering from psoriasis. Collegium Antropologicum, 35(2), 81–85.PubMed
50.
Zeljko-Penavic, J., Situm, M., Simic, D., & Vurnek-Zivkovic., M. (2010). Quality of life in psoriatic patients and the relationship between type I and type II psoriasis. Collegium Antropologicum, 34(1), 195–198.PubMed
51.
Tennvall, G., Hjortsberg, C., Bjarnason, A., Gniadecki, R., Heikkila, H., & Jemec, G. B. et al. (2013). Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three nordic countries. Acta Dermato-Venereologica, 93, 442–445.CrossRef
Metadaten
Titel
Health-related quality of life in patients with psoriasis: a systematic review of the European literature
verfasst von
Montse Obradors
Carles Blanch
Marta Comellas
Montse Figueras
Luis Lizan
Publikationsdatum
03.06.2016
Verlag
Springer International Publishing
Erschienen in
Quality of Life Research / Ausgabe 11/2016
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-016-1321-7

Weitere Artikel der Ausgabe 11/2016

Quality of Life Research 11/2016 Zur Ausgabe

OriginalPaper

Prospective associations of objectively assessed physical activity at different intensities with subjective well-being in older adults

OriginalPaper

Measuring health-related quality of life in patients with conservatively managed stage 5 chronic kidney disease: limitations of the Medical Outcomes Study Short Form 36: SF-36

Review

EQ-5D in Central and Eastern Europe: 2000–2015

OriginalPaper

The benefits of personal strengths in mental health of stressed students: A longitudinal investigation

OriginalPaper

Patient-reported outcomes and surgical triage: A gap in patient-centered care?

OriginalPaper

The development and acceptability of symptom management quality improvement reports based on patient-reported data: an overview of methods used in PROSSES